

Recent University of Maryland Hematology/Oncology Fellowship Publications

1. **Bade NA**, Yared JA. Unexpected babesiosis in a patient with worsening anemia after allogeneic hematopoietic stem cell transplantation. *Blood*. 2016;128:1019.
2. **Bade NA**, Giffi VS, Baer MR, Zimrin AB, Law JY. Thrombotic microangiopathy in the setting of human immunodeficiency virus infection: High incidence of severe thrombocytopenia. *J Clin Apher*. 2018;33:342-348.
3. **Bade NA**, Bade NA, Lu C, Patzke CL, Baer MR, Duong VH, Law JY, Lee ST, Sausville EA, Zimrin AB, Duffy AP, Lawson J, Emadi A. Optimizing pegylated asparaginase use: An institutional guideline for dosing, monitoring, and management. *J Oncol Pharm Pract*. 2020 Jan;26:74-92.
4. **Bukhari A**, **El Chaer F**, Koka R, Singh Z, Hutnick E, Ruehle K, Lee ST, Kocoglu MH, Shanholtz C, Badros A, Hardy N, Yared J, Rapoport AP, Dahiya S. Rapid relapse of large B-cell lymphoma after CD19 directed CAR-T-cell therapy due to CD-19 antigen loss. *Am J Hematol*. 2019;94:E273-E275.
5. **Bukhari A**, Lee ST. Blinatumomab: a novel therapy for the treatment of non-Hodgkin's lymphoma. *Expert Rev Hematol*. 2019;12:909-918.
6. **Ding J**, Baer MR, Hess JR, Zimrin AB. Intravenous immunoglobulin as salvage therapy for refractory thrombotic thrombocytopenic purpura. *Am J Hematol*. 2018;93:E77-E79.
7. **Ding J**, Kumar AJ, Wilding E, Lee ST, Law JY. Multi-Organ Failure as the Initial Presentation of Lymphocyte-Depleted Hodgkin Lymphoma in Two Patients with Human Immunodeficiency Virus. *Acta Haematol*. 2020;143:184-188.
8. Duong VH, **Holtzman NG**, Koka R, Singh ZN, Zou Y, Emadi A, Rapoport AP, Kocoglu MH, Baer MR, Badros AZ. Characteristics and outcomes of therapy related-myeloid neoplasms after treatment for multiple myeloma. *Leuk Lymphoma*. 2019 Dec;60:3577-3580.
9. **El Chaer F**, **Holtzman NG**, Baer MR, Zimrin AB, Law JY. Sickle Cell Disease Complicated by Iron Overload: An Under-Recognized Risk Factor for *Vibrio vulnificus* infection. *Acta Haematol*. 2018;139:199-200.
10. **El Chaer F**, **Holtzman NG**, Sausville EA, Law JY, Lee ST, Duong VH, Baer MR, Koka R, Singh ZN, Hardy NM, Emadi A. Relapsed Philadelphia Chromosome-Positive Pre-B-ALL after CD19-Directed CAR-T Cell Therapy Successfully Treated with Combination of Blinatumomab and Ponatinib. *Acta Haematol*. 2019; 141:107-110.
11. **El Chaer F**, Siegel A, **Holtzman NG**, **Bukhari A**, **Lutfi F**, Shah NG, Yared JA, Rapoport AP, McCurdy MT, Dahiya S. Severe dysautonomia as a manifestation of neurotoxicity after CAR-T cell therapy for diffuse large B-cell lymphoma. *Am J Hematol*. 2020;95:E146-E148.
12. **Elder SA**, O'Brien JJ, Singh ZN, Wilding E, Zimrin AB, Law JY, Baer MR. Babesiosis Masquerading as Evans Syndrome. *Am J Med*. 2019;132:e616-e617.
13. **Elder SA**, Yared J, Hardy N, Rapoport A, **Bukhari A**, Dahiya S. Rejection, but in a Different Direction: Graft-Versus-Host Disease after Solid Organ Transplantation Mimicking an Infection. *Am J Med*. 2019;132:e852-e853.
14. Emadi A, **Bade NA**, Stevenson B, Singh Z. Minimally Myelosuppressive Asparaginase-Containing Induction Regimen for Treatment of a Jehovah's Witness with mutant IDH1/NPM1/NRAS Acute Myeloid Leukemia. *Pharmaceuticals*. 2016;9(1):12.

15. **Holtzman NG**, Rapoport AP. Genomics trumps clinical criteria in BMT? Nyet! *Blood*. 2017;129(17):2335-2336.
16. **Holtzman NG, El Chaer F**, Baer MR, Ali O, Patel A, Duong VH, Sausville EA, Singh ZN, Koka R, Zou YS, Etemadi A, Emadi A. Peripheral blood blast rate of clearance is an independent predictor of clinical response and outcomes in acute myeloid leukemia. *Br J Haematol*. 2020 Mar;188:881-887.
17. **Holtzman NG**, Xie H, Bentzen S, Kesari V, **Bukhari A, El Chaer F, Lutfi F**, Siglin J, Hutnick E, Gahres N, Ruele K, Ahmad H, Shanholtz C, Kocoglu MH, Badros AZ, Yared JA, Hardy NM, Rapoport AP, Dahiya S. Immune Effector Cell-Associated Neurotoxicity Syndrome after Chimeric Antigen Receptor T-cell Therapy for Lymphoma: Predictive Biomarkers and Clinical Outcomes. *Neuro Oncol*. 2020 Aug 5.
18. **Karne S, Mainor CB**, Baer MR. Development of hypercalcemia in a patient receiving Peginterferon alfa-2a therapy for polycythemia vera. *Pharmacotherapy*. 2016;36(6):54-7.
19. Koka R, **Mainor CB**, Banerjee A, Baer MR, Zou YS. Concomitant amplification of the MLL gene on a ring chromosome and a homogeneously staining region (hsr) in acute myeloid leukemia: mechanistic implications. *Leuk Lymphoma*. 2017; 58(5):1250-3.
20. Koka R, **Bade NA**, Sausville EA, Ning Y, Zou Y. Unique amplification of BCR-ABL1 gene fusion in a case of T-cell acute lymphoblastic leukemia. *Mol Cytogenet*. 2017;10:39.
21. **Lam VK**, Bentzen SM, Mohindra P, Nichols EM, Bhooshan N, Vyfhuis M, **Scilla KA**, Feigenberg SJ, Edelman MJ, Feliciano JL. Obesity Is Associated With Long-Term Improved Survival in Definitively Treated Locally Advanced Non-Small Cell Lung Cancer (NSCLC). *Lung Cancer*. 2017;104:52-57.
22. Li AY, **McCusker MG**, Russo A, Scilla KA, Gittens A, Arensmeyer K, Mehra R, Adamo V, Rolfo C. RET Fusions in solid tumors. *Cancer Treat Rev*. 2019;81:101911.
23. **McCusker MG**, Scilla KA, Simone CB 2nd, Sachdeva A, Miller KD, Burke AP, Rolfo C. Proton Beam Therapy and Immune Checkpoint Inhibitors in Malignant Pleural Mesothelioma. *J Thorac Oncol*. 2019;14:e185-e187.
24. **McCusker MG**, Russo A, Scilla KA, Mehra R, Rolfo C. How I Treat ALK-Positive non-small cell lung cancer. *ESMO Open*. 2019;4:e000524.
25. **McCusker MG**, Orkoulas-Razis D, Mehra R. Potential of Pembrolizumab in Metastatic or Recurrent Head and Neck Cancer: Evidence to Date. *Onco Targets Ther*. 2020;13:3047-3059.
26. Niyongere S, **Sanchez-Petitto G**, Masur J, Baer MR, Duong VH, Emadi A. Frontline Blinatumomab in Older Patients with Philadelphia Chromosome-Negative B-cell Acute Lymphoblastic Leukemia. *Pharmaceuticals (Basel)*. 2020;13:124.
27. Russo A, **McCusker MG**, Scilla KA, Arensmeyer KE, Mehra R, Adamo V, Rolfo C. Immunotherapy in Lung Cancer: From a Minor God to the Olympus. *Adv Exp Med Biol*. 2020;1244:69-92.
28. **Sanchez-Petitto G**, Drachenberg CB, Mannuel HD, Law JY, Zimrin AB, Baer MR. An Unusual Presentation of Paroxysmal Nocturnal Hemoglobinuria. *Br J Haematol*. 2020;188:347.
29. **Sanchez-Petitto G, Holtzman NG, Bukhari A**, Brown M, Morales MK, Koka M, Yared JA, Dahiya S, Rapoport AP, Hardy NM. Toxoplasma-induced hemophagocytic lymphohistiocytosis after haploidentical allogeneic stem cell transplantation. *Transpl Infect Dis*. 2020 Apr;22:e13242.

30. **Sanchez-Petitito G**, Hardy N, Burke A, **McCusker MG**, Li A, Badros AZ. Eosinophilic Myocarditis in a Patient with Multiple Myeloma. *Clin Lymphoma Myeloma Leuk*. 2020;20:e292-e294.
31. **Scilla KA**, Bentzen SM, Lam VK, Mohindra P, Nichols EM, Vyfhuis MA, Bhooshan N, Feigenberg SJ, Edelman MJ, Feliciano JL. Neutrophil-lymphocyte ratio (NLR) is a prognostic marker in patients with locally advanced (Stage IIIA & IIIB) non-small cell lung cancer treated with combined modality therapy. *The Oncologist*. 2017;22:737-742.
32. **Scilla KA**, Zandberg DP, Bentzen SM, Mainor C, Heath J, Ioffe OB, Cellini AL, Edelman MJ, Riedel DJ, Feliciano JL. Case-control study of PD-1, PD-L1 and B7-H3 expression in lung cancer patients with and without human immunodeficiency virus (HIV) infection. *Lung Cancer*. 2018;123:87-90.
33. Siglin J, **Bukhari A**, **Lutfi F**, **Holtzman NG**, Shanholtz C, Yared JA, Hardy NM, Rapoport AP, Dahiya S. C-reactive protein: not always a reliable marker of ongoing cytokine release syndrome in CAR-T therapy following IL-6 blockade. *Leuk Lymphoma*. 2020;Apr 28:1-3.
34. **Soleimani A**, Koka M, Singh ZN, Kesari V, Badros A. Biologic Implications of t(11;14) in Multiple Myeloma Explained with a Case of Refractory Disease Sensitive to Venetoclax. *Clin Lymphoma Myeloma Leuk*. 2020;S2152-2650.
35. **Weart TC**, Miller KD, Simone CB. Spotlight on dabrafenib/trametinib in the treatment of non-small-cell lung cancer: place in therapy. *Cancer Manag Res*. 2018;10:647-652.